Drugs / RX-518
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02926768 | Sep 2016 → Sep 2020 | adenocarcinoma, non-small cell lung carcinoma | Checkpoint Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RX-518 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297486 ↗ |
| Known as | CK-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02926768 ↗ |
| Known as | Olafertinib | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297486 ↗ |
| Action | Inhibit | “CK-101 is a novel, potent, small molecule tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing...” NCT02926768 ↗ |
| Modality | Small molecule | “CK-101 is a novel, potent, small molecule tyrosine kinase inhibitor (TKI)” NCT02926768 ↗ |
| Route | Oral | “oral CK-101 administered daily” NCT02926768 ↗ |
| Target | EGFR | “selectively targets mutant forms of the epidermal growth factor receptor (EGFR)” NCT02926768 ↗ |